Larry S. Schlesinger, MD is an internationally recognized authority in infectious diseases. He became Professor, President and CEO of Texas Biomedical Research Institute in San Antonio, TX in 2017 and is leading a transformational process focused on scientific growth and cultural change, a new campus master plan and new research and education programs. Since his arrival, Texas Biomed has added over 20 new faculty members, tripled funding and invested in ~200M in campus improvements, faculty and staff recruitment and new programs. He is very active in city-wide initiatives that advance the biosciences sector of San Antonio.

Dr. Schlesinger is a leading physician scientist whose research program focuses on how the lung environment shapes alveolar macrophage biology in the context of the pathogenesis of tuberculosis and diseases caused by other intracellular pathogens that subvert lung immune mechanisms. He translates these discoveries into new platforms and assays for host-directed therapies for infectious diseases. He is a prolific scholar, having authored 250 peer-reviewed articles and reviews, served as editor of 2 books and has written several chapters in leading textbooks. He has been continually funded by the NIH and other federal agencies as well as private foundations such as the Bill & Melinda Gates Foundation for more than 30 years. He is a past NIH NIAID Council member, Fellow of the American Association for the Advancement of Science, Infectious Diseases Society of America, Association of American Physicians and American Academy of Microbiology. He has trained ~175 individuals and led NIH-funded training programs. He served as director of the Ohio State University NIH-supported MSTP in 2011-2017, was a member and chair elect of the AAMC GREAT MD-PhD Section Steering Committee and is a current member of the BOD for APSA.